# OnCo record nct05910827 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05910827/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05910827", "NCT05910827" ;
  schema:name "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers"@en ;
  schema:description "A phase 1/2 trial of HMBD-001, Docetaxel, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Hummingbird Bioscience, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05910827/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05910827> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-02-05" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/cutaneous-scc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/cetuximab/> ;
  onco:companies <https://onco.cc/companies/hummingbird-bioscience/> .